棕榈酰三肽-1 (PALMITOYL TRIPEPTIDE-1) 在全球 7 大法域的官方全成分标签名称是什么？

中国 NMPA《已使用化妆品原料目录 (IECIC)》标准中文名为 '棕榈酰三肽-1'，美国 PCPC 与欧盟 CosIng 标准 INCI 为 'PALMITOYL TRIPEPTIDE-1'，日本 JCIA 表示名称为 'PALMITOYL TRIPEPTIDE-1'。

棕榈酰三肽-1 (PALMITOYL TRIPEPTIDE-1) 在中、韩、欧、美、日、东盟的法定监管状态 (Layer 1) 如何？

6 大法域监管汇总 — 中国(CN): allowed，韩国(KR): none，欧盟(EU): none，美国(US): none，日本(JP): none，东盟(ASEAN): none。

棕榈酰三肽-1 (PALMITOYL TRIPEPTIDE-1) 的常规配方添加量 (Layer 3) 与最佳稳定 pH 窗口是多少？

在代表性剂型 (emulsion_cream) 中常规添加量为 0.001%–0.15%（中位数 0.01%），最佳稳定 pH 范围为 4.5–7.5。

多肽与蛋白 (Peptide)

PALMITOYL TRIPEPTIDE-1

Q: 棕榈酰三肽-1 (PALMITOYL TRIPEPTIDE-1) 有哪些配伍禁忌 (Incompatibilities) 与协同增效组合？

推荐协同组合包括 PALMITOYL TETRAPEPTIDE-7, RETINOL, CERAMIDE NP, NIACINAMIDE；配伍禁忌注意：Palmitoyl C16 tail enhances stratum corneum partitioning; typically incorporated as a pre-solubilized glycolic solution at < 45°C。

中国 NMPA《已使用化妆品原料目录 (IECIC)》标准中文名: 棕榈酰三肽-1 (序号 #8747)

皮肤调理剂

[EU CosIng Official Definition] Palmitoyl Tripeptide-1 is the reaction product of palmitic acid and Tripeptide-1

核心法规与安全结论 (Executive Fact Box)AEO / GEO CITATION ANCHOR

化妆品中棕榈酰三肽-1 (PALMITOYL TRIPEPTIDE-1) 的全球法规限值与配方应用标准是什么？

棕榈酰三肽-1（标准 INCI: PALMITOYL TRIPEPTIDE-1，CAS 号: 147732-56-7）是化妆品配方中主要用作皮肤调理剂的核心成分。受中国 NMPA（已使用/准用）、韩国 MFDS（未列管）及欧盟 CosIng（未列管）等 6 大法域法定标准监管，常规建议添加量为 0.001–0.15%（最佳稳定窗口 pH 4.5–7.5）。

全球 7 轨官方全成分标签名称对照表

严格采用各国政府官方目录原名 · 严禁机器翻译

7-Track Official Statutory Label Names for PALMITOYL TRIPEPTIDE-1
法域与监管轨道	官方公告全成分标准名称	一键复制
① 韩国 (MFDS 化妆品标准名称)	PALMITOYL TRIPEPTIDE-1 (KR MFDS Registered)
② 韩国旧名称历史 (301 重定向)	Former KR Nomenclature Redirect Active	—
③ 欧盟 (EU CosIng EC 1223/2009)	PALMITOYL TRIPEPTIDE-1
④ 美国普通化妆品 (US PCPC / MoCRA INCI)	PALMITOYL TRIPEPTIDE-1
⑤ 美国 OTC 防晒/祛痘专论活性物名称 (FDA OTC)	— (非美国 OTC 专论活性成分 / 普通化妆品原料)	—
⑥ 中国 (NMPA《已使用化妆品原料目录 IECIC》标准中文名)	棕榈酰三肽-1
⑦ 日本普通化妆品 / 医药部外品 (JCIA / MHLW)	PALMITOYL TRIPEPTIDE-1 (标准 INCI 参照)

Layer 1 — 全球 6 大法域法定限值与监管状态

Layer 1 Statutory Regulatory Limits Across 6 Regions for PALMITOYL TRIPEPTIDE-1
法域	监管状态	法定限值	适用条件与法定依据来源
韩国 (MFDS)	未列管	GMP	已列入官方化妆品原料目录 (按 GMP 规范使用)
欧盟 (EU)	未列管	GMP	已列入官方化妆品原料目录 (按 GMP 规范使用)
美国 (FDA)	未列管	GMP	已列入官方化妆品原料目录 (按 GMP 规范使用)
中国 (NMPA)	已使用/准用	GMP	IECIC Entry #8747
日本 (MHLW)	未列管	GMP	已列入官方化妆品原料目录 (按 GMP 规范使用)
东盟 (ACD)	未列管	GMP	已列入官方化妆品原料目录 (按 GMP 规范使用)

Layer 2 — 毒理评估与历史最高使用量 (CN IECIC / US CIR / EU SCCS)

“欧盟 SCCS 安全评估上限”代表消费者安全科学委员会判定安全边际 (MoS≥100) 的毒理阈值；“美国 CIR 市售最高报告浓度”与“中国 IECIC 最高历史使用量”代表已上市化妆品的最高实际使用浓度。

Layer 2 Toxicological & Historical Safe Use Concentrations for PALMITOYL TRIPEPTIDE-1
安全评估依据	适用范围与剂型	评估浓度范围	评估结论与文献档案
中国 IECIC 最高历史使用量	leave_on	≤ 0.2%	安全判定 (MoS≥100)NMPA IECIC (2025) Entry 08941 (2025)
中国 IECIC 最高历史使用量	rinse_off	≤ 0.1%	安全判定 (MoS≥100)NMPA IECIC (2025) Entry 08941 (2025)

⚠️ 仅供参考 (免责声明): 本词典中的原料名称、法规限值与配比指南仅供研发参考。鉴于法规修订时差或潜在数据误差，实际配方设计、标签印制及备案前请务必核实主管部门最新官方公告原文；因使用本词典信息产生的任何问题，运营方概不承担法律责任。

Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Emulsion / Creamn=58

Min 0.001% · Q1 0.005% · Median 0.01% · Q3 0.05% · Max 0.15%

Emulsion / Cream — Lipophilic matrikine signaling peptide stimulating Type I/III collagen synthesis

Verified Source: Sederma Matrixyl 3000 Technical Monograph & CIR Palmitoyl Oligopeptides Assessment (cir_safety) · Sederma/Croda 44 · Evonik 14

Typical Median: 0.01%

Layer 3 — 剂型常规配比指南与理化配伍性

Layer 3 Formulation Concentration Quartiles by Product Category for PALMITOYL TRIPEPTIDE-1
剂型分类	Min – Q1 – Median – Q3 – Max (%)	配方作用与机理	Source ID
剂型组 B — 乳液 / 面霜 (O/W · W/O)	0.001% · 0.005% · 0.01% · 0.05% · 0.15%	Lipophilic matrikine signaling peptide stimulating Type I/III collagen synthesis	Sederma Matrixyl 3000 Technical Monograph & CIR Palmitoyl Oligopeptides Assessment

Cutaneous Permeation Science (500 Dalton Rule)MW: 578.8 Da · LogP: 2.8

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Molecular Weight & LogP Permeation Diagnosis

Macromolecule (578.8 Da > 500 Da) — Transdermal Booster Required

Co-formulating with 0.1–0.5% Hydrolyzed Sponge (Bio-Spicule, 180–250 µm) creates transient micro-channels across the stratum corneum, delivering actives directly into the papillary dermis (PMID: 34112845).

Estimated Target Depth

180–250 µm

Optimal Delivery System

Bio-Spicule + Liposome

Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Soluble in glycols/surfactant premixes (supplied as 100~1000 ppm solution)

Optimal Formulation pH Stability Window (0–14)pH 4.5 – 7.5

Outside pH 4.5–7.5, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 50°C

Thermally stable up to 50°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator

O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)

Simulate HLB:HLB 11.5

Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation

Intercellular Lipid & Hydration Matrix

→

TEWL Reduction & Barrier Conditioning

2. Homeostasis Modulation⊣ Inhibition / Blockade

Oxidative Stress (ROS) & Irritant Cascade

⊣

Cutaneous Soothing & Homeostasis

Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

+ PALMITOYL TETRAPEPTIDE-7 + RETINOL + CERAMIDE NP + NIACINAMIDE

代表性商品名参考 (商标法第90条第1款第2项说明性标示)

Matrixyl® 3000 (with Palmitoyl Tetrapeptide-7)Biopeptide CL™

商品名仅供配方师识别原料规格参考，商标权归各原厂商所有。

学术与毒理综合摘要

Tier 1 Synthesis

本综述严格基于与该原料关联的 NIH PubMed 同行评审文献摘要及官方毒理学评估档案编写。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: PALMITOYL TRIPEPTIDE-1 | CAS No.: 147732-56-7 | EC No.: N/A - Origin: PEPTIDE | Functions: Skin Conditioning - Physicochemical Profile: Formula C30H54N6O5 | MW 578.8 g/mol | LogP 2.8 | Ionic Nature: amphoteric | PubChem CID 9862849 - Official Regional Label Names: US [PALMITOYL TRIPEPTIDE-1] · EU [PALMITOYL TRIPEPTIDE-1] · CN [棕榈酰三肽-1] · JP [-] · JP Quasi-Drug [-] ■ [2. Dermatological Mechanism of Action & Functional Role] - Palmitoyl Tripeptide-1 is the reaction product of palmitic acid and Tripeptide-1 Classified under origin 'peptide', it acts within the cosmetic vehicle or stratum corneum to deliver performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 8747 (棕榈酰三肽-1)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 0.2% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 0.1% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [emulsion_cream] Typical range: 0.001 ~ 0.15% (Median 0.01%, Ref: Sederma Matrixyl 3000 Technical Monograph & CIR Palmitoyl Oligopeptides Assessment) — Lipophilic matrikine signaling peptide stimulating Type I/III collagen synthesis ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Cool-down Phase (< 45°C) - Optimal pH Range: pH 4.5 ~ 7.5 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM - Incompatibility / Caution: Palmitoyl C16 tail enhances stratum corneum partitioning; typically incorporated as a pre-solubilized glycolic solution at < 45°C - Synergy Pairings: PALMITOYL TETRAPEPTIDE-7, RETINOL, CERAMIDE NP, NIACINAMIDE | Reference Trade Names: Matrixyl® 3000 (with Palmitoyl Tetrapeptide-7), Biopeptide CL™ ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 41527525 (2026, J Cosmet Dermatol): Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism

关联同行评审文献 (NIH PubMed) (1)

Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism [PMID: 41527525 · 2026]

Wang C, Song T, Zhang Y, Li N, Xie L, Xie M, Jiang X, Lü G, Meng Y, Wang C, Yue L, Yang W, Li Y, Wu Y, Chen L · J Cosmet Dermatol (2026)

Collagen is essential for maintaining skin structure and function, and the circadian rhythm is known to regulate a wide range of physiological processes. To investigate whether collagen metabolism in human skin fibroblasts exhibits circadian regulation, and to evaluate whether the time-coordinated application of baicalin at daytime and palmitoyl tripeptide-1 (PT-1) at nighttime synergistically promotes collagen fiber formation and improves overall skin quality. A circadian-synchronized human skin fibroblast model was established. The expression of collagen metabolism-related genes was analyzed using qPCR and immunofluorescence. Subsequently, an 8-week topical application study was conducted in mice using a regimen of daytime baicalin and nighttime PT-1. Finally, a clinical trial involving 30 female participants was conducted, employing the same time-coordinated application scheme. Fibroblasts exhibited opposing day-night rhythms: genes for collagen assembly (e.g., LOX) peaked during the day, while those involved in synthesis/secretion (e.g., Sec61a2, Mia3, Pde4d, Vps33b) and degradation (e.g., CTSK, MMP1) peaked at night. Time phase-dependent interventions showed baicalin enhanced daytime assembly, while PT-1 boosted nighttime synthesis. In mice, a timed day-night combination therapy increased collagen fiber density. Clinical trial (n = 30) confirmed the efficacy, showing significant improvements in skin luminance (+16.29%), nasolabial fold depth (-36.35%), and firmness (R2: +24.35%). Collagen metabolism is regulated by circadian rhythms. Chronomodulated baicalin and PT-1 application synergistically optimize collagen metabolism and improve skin quality.

常见问题解答 (FAQ)

Q1. 棕榈酰三肽-1 (PALMITOYL TRIPEPTIDE-1) 在全球 7 大法域的官方全成分标签名称是什么？: 中国 NMPA《已使用化妆品原料目录 (IECIC)》标准中文名为 '棕榈酰三肽-1'，美国 PCPC 与欧盟 CosIng 标准 INCI 为 'PALMITOYL TRIPEPTIDE-1'，日本 JCIA 表示名称为 'PALMITOYL TRIPEPTIDE-1'。
Q2. 棕榈酰三肽-1 (PALMITOYL TRIPEPTIDE-1) 在中、韩、欧、美、日、东盟的法定监管状态 (Layer 1) 如何？: 6 大法域监管汇总 — 中国(CN): allowed，韩国(KR): none，欧盟(EU): none，美国(US): none，日本(JP): none，东盟(ASEAN): none。
Q3. 棕榈酰三肽-1 (PALMITOYL TRIPEPTIDE-1) 的常规配方添加量 (Layer 3) 与最佳稳定 pH 窗口是多少？: 在代表性剂型 (emulsion_cream) 中常规添加量为 0.001%–0.15%（中位数 0.01%），最佳稳定 pH 范围为 4.5–7.5。
Q4. 棕榈酰三肽-1 (PALMITOYL TRIPEPTIDE-1) 有哪些配伍禁忌 (Incompatibilities) 与协同增效组合？: 推荐协同组合包括 PALMITOYL TETRAPEPTIDE-7, RETINOL, CERAMIDE NP, NIACINAMIDE；配伍禁忌注意：Palmitoyl C16 tail enhances stratum corneum partitioning; typically incorporated as a pre-solubilized glycolic solution at < 45°C。